Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: A patient report and review of the literature

Masanori Adachi, Koji Muroya, Yumi Asakura, Kenji Sugiyama, Keiko Homma, Tomonobu Hasegawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.

Original languageEnglish
Pages (from-to)138-142
Number of pages5
JournalHormone Research in Paediatrics
Volume82
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Genetic Association Studies
Mutation
Spironolactone
Hyperaldosteronism
Genotype
Hypertrophy
Genes
Hypertension
Polyuria
Hypokalemia
Missense Mutation
Sodium
Phenotype
Familial Hyperaldosteronism
Pharmaceutical Preparations
Therapeutics

Keywords

  • Endocrine hypertension
  • Familial hyperaldosteronism
  • KCNJ5
  • Kir3.4
  • Primary aldosteronism

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation : A patient report and review of the literature. / Adachi, Masanori; Muroya, Koji; Asakura, Yumi; Sugiyama, Kenji; Homma, Keiko; Hasegawa, Tomonobu.

In: Hormone Research in Paediatrics, Vol. 82, No. 2, 2014, p. 138-142.

Research output: Contribution to journalArticle

@article{5c57b23932b6488b8a945c58b313e6cf,
title = "Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: A patient report and review of the literature",
abstract = "Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.",
keywords = "Endocrine hypertension, Familial hyperaldosteronism, KCNJ5, Kir3.4, Primary aldosteronism",
author = "Masanori Adachi and Koji Muroya and Yumi Asakura and Kenji Sugiyama and Keiko Homma and Tomonobu Hasegawa",
year = "2014",
doi = "10.1159/000358197",
language = "English",
volume = "82",
pages = "138--142",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation

T2 - A patient report and review of the literature

AU - Adachi, Masanori

AU - Muroya, Koji

AU - Asakura, Yumi

AU - Sugiyama, Kenji

AU - Homma, Keiko

AU - Hasegawa, Tomonobu

PY - 2014

Y1 - 2014

N2 - Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.

AB - Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.

KW - Endocrine hypertension

KW - Familial hyperaldosteronism

KW - KCNJ5

KW - Kir3.4

KW - Primary aldosteronism

UR - http://www.scopus.com/inward/record.url?scp=84928162344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928162344&partnerID=8YFLogxK

U2 - 10.1159/000358197

DO - 10.1159/000358197

M3 - Article

C2 - 24819081

AN - SCOPUS:84928162344

VL - 82

SP - 138

EP - 142

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 2

ER -